Teva Reports Encouraging Data From Multiple Sclerosis Study
Teva Pharmaceutical Industries has announced new positive data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis, which proves robust efficacy and safety of Copaxone.
Findings demonstrated that more than 80% of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years.
The majority of the 100 patients in the study experienced either stable or improved disability rates over the duration of the study, as measured by the Expanded Disability Status Scale, as well as a 78% reduction in annualized relapse rate from baseline.
These data further confirm the benefits of long-term, daily use of Copaxone in treating the relapsing-remitting multiple sclerosis, while reinforcing the already established safety profile of the therapy, the company said. Based on the positive results of these data, patients will continue to be followed to 20 years of treatment.
Corey Ford, primary investigator of the study, said: “These data are of value to the multiple sclerosis community, as they reassure the ability of Copaxone to effectively slow the natural progression of this disease using daily treatment. Until we find a cure for multiple sclerosis, patients and physicians need a treatment that can safely provide a clinical benefit over the long-term.”